A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy (NCCH1503,Lemon trial)

ABSTRACT: Interventions: 24mg of lenvatinib is orally taken once daily. Primary outcome(s): Disease control rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2638699 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR